NAUT — Nautilus Biotechnology, Inc.
$3.24+24.62%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NAUT in the TickerWise workspace.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 134
- Website: https://www.nautilus.bio
Latest SEC filings for NAUT
Latest NAUT news
- Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 Read article
- NAUT Stock Pops As Analysts Back AI Proteomics Bet
- Roth Capital Initiates Nautilus Biotechnolgy at Buy
- Roth/MKM initiates Nautilus Biotechnology stock with buy rating
- Roth/MKM initiates Nautilus Biotechnology stock with buy rating By Investing.com
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.